New hope for cancer patients: drugs may cut steroid dependency from immunotherapy
NCT ID NCT04375228
First seen Feb 06, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tests whether rituximab or tocilizumab can help people with advanced solid tumors stop using steroids for immune-related side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can discontinue steroids within 4 weeks. The goal is to ease side effects and improve quality of life without long-term steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Johns Hopkins
Baltimore, Maryland, 21224, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
Conditions
Explore the condition pages connected to this study.